


Introducing



Engineered Cells

SYNTHEGO

Full Stack
Genome
Engineering



[Synthego.com/cshl](https://synthego.com/cshl)

Transforming Cutting-Edge Research into Industry-Leading Therapeutics

*The Industry's First Non-viral Solution That Can Help
Accelerate Your Cell Product to the Clinic*

Delivering the ideal combination of advanced technologies, scientific expertise, and technical support – MaxCyte offers a powerful platform to help accelerate your path to the clinic and obtain the therapeutic index you require.

- High efficiency and viability
- Reproducibility
- Seamless scalability
- Proven clinical success

www.MaxCyte.com

Any Cell. Any Molecule. Any Scale.®

 **MaxCyte**®





2019 RNA Meetings at CSHL



aerial view of CSHL sandspit and inner harbor during meeting social

RNA Control & Regulation

84th CSHL Symposium May 29 - June 3, 2019 Poster abstracts due March 8

Terri Grodzicker, David Stewart, Bruce Stillman *Cold Spring Harbor Laboratory*

Topics

RNA-Based Structures

RNA Modifications

Nuclear Localization of RNA

Quality Control & Editing

RNA & Gene Regulation

Cotranscriptional Splicing

Intron / Exon Boundaries

Alternative Polyadenylation

Transposon Control

Small Noncoding RNAs

Long Noncoding RNAs

RNA & Development

Membrane-Less Organelles

Phase Separation

RNA-Based Diseases

Novel RNA functions

meetings.cshl.edu/rnasymp

RNA & Oligonucleotide Therapeutics

March 27 - 30, 2019 Abstracts due January 11

Annemieke Aartsma-Rus, *Leiden University Medical Center* **Masad Damha**, *McGill University*

Matthew Stanton, *Generation Bio* **Laura Sepp-Lorenzino**, *Vertex Pharmaceuticals Inc.*

Topics

Nucleic Acid Chemistry

Delivery

Emerging Therapeutics

Preclinical Development

Clinical Programs

Safety

meetings.cshl.edu/rnatx19

Eukaryotic mRNA Processing

August 20 - 24, 2019 Abstracts due May 31

Alberto Kornblihtt, *University of Buenos Aires, Argentina*

Jens Lykke-Andersen, *University of California, San Diego*

Karla Neugebauer, *Yale University*

Topics

Alternative splicing

Mechanisms of RNA Splicing

RNA-Protein interactions

RNP complexes

3' end processing

RNA modification

RNA structure

Co-transcriptional RNA processing

RNA turnover & quality control

Small RNA biogenesis and function

Viruses and RNA processing

meetings.cshl.edu/mrna19



meeting participants at social

The AACR logo consists of the letters "AACR" in a bold, white, sans-serif font, set against a solid green rectangular background.

American Association
for Cancer Research™

ANNUAL MEETING

2019  ATLANTA

March 29-April 3 | Georgia World Congress Center | Atlanta, GA

The background of the top half of the poster is composed of several large, overlapping geometric shapes in shades of green, blue, and grey. A stylized world map is visible in the upper right corner. Below the header, there are two triangular images: the left one shows crumpled blue paper on a dark surface, and the right one shows a man in a white lab coat looking at a skeletal model.

Join us in Atlanta for the latest innovative and
inspiring cancer research from around the world

Register Today!

Become a Member! Join the AACR and receive a discount on registration

The AACR Annual Meeting highlights the work of the greatest minds in cancer science and medicine from institutions all over the world. This meeting presents the many scientific discoveries across the breadth of cancer research—from prevention, early detection, and interception; to cancer biology, translational, and clinical studies; to survivorship, population science, and advocacy. This year's program, with the theme of "Integrative Cancer Science • Global Impact • Individualized Patient Care," will be a comprehensive, cutting-edge scientific event that you will not want to miss!

INTEGRATIVE CANCER SCIENCE
GLOBAL IMPACT
INDIVIDUALIZED PATIENT CARE



#AACR19



AACR.org/AnnualMeeting

Superior mRNA Therapeutics Start **HERE**

TriLink® CleanCap™ technology sets a new standard for superior mRNA translation.




COST: Lowest cost per milligram of biologically active Cap 1 mRNA due to increased yield - **lower than ARCA!**

TIME: Simplified transcription process - "Single pot" reaction to produce a Cap 1 structure


EFFICIENCY: 90-99% capping efficiency. Reduced cellular innate immune response with natural Cap 1 mRNA




Successful development of mRNA therapeutics relies on reproducible, high-efficiency production of capped mRNA. CleanCap™ uses a new co-transcriptional chemical process for the highest level of mRNA capping:



LC-MS Capping Analysis



ARCA EGFP mRNA



CleanCap™ EGFP mRNA

Available as:

CleanCap™
mRNA -
catalog &
custom



CleanCap™
reagents



CleanCap™
synthesis
services



The comparison is clear.

Visit **CleanCapmRNA.com** to see even more proof.